{
  "success": true,
  "pagesUsed": [
    0,
    1,
    2,
    3,
    4,
    5,
    6,
    7,
    8,
    9,
    10,
    11,
    12,
    13,
    14,
    15,
    16,
    17,
    18,
    19,
    20,
    21,
    22,
    23,
    24,
    25,
    26,
    27,
    28,
    29,
    30,
    31,
    32,
    33,
    34,
    35,
    36,
    37,
    38,
    39,
    40,
    42,
    43,
    44,
    49,
    53,
    60,
    63,
    64,
    65,
    66,
    67,
    68,
    70,
    78,
    89
  ],
  "modelUsed": "gemini-3-flash",
  "data": {
    "timeAnchors": [
      {
        "id": "anchor_1",
        "definition": "First administration of investigational product",
        "anchorType": "FirstDose",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 60,
        "sourceText": "first dose of \nstudy drug",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_2",
        "definition": "Date of subject randomization",
        "anchorType": "Randomization",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 40,
        "sourceText": "randomization visit",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_3",
        "definition": "Baseline visit/assessment",
        "anchorType": "Baseline",
        "classification": "Visit",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 50,
        "sourceText": "Baseline assessment",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_4",
        "definition": "Informed consent obtained",
        "anchorType": "InformedConsent",
        "classification": "Event",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 10,
        "sourceText": "Informed \nconsent",
        "encounterId": null,
        "activityId": null
      },
      {
        "id": "anchor_5",
        "definition": "procedure",
        "anchorType": "Custom",
        "classification": "Conceptual",
        "timelineId": null,
        "dayValue": 1,
        "intraDayOrder": 100,
        "sourceText": "procedure",
        "encounterId": null,
        "activityId": null
      }
    ],
    "repetitions": [
      {
        "id": "rep_daily_1",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "once daily"
      },
      {
        "id": "rep_daily_2",
        "type": "Daily",
        "interval": "P1D",
        "sourceText": "od"
      },
      {
        "id": "rep_interval_1",
        "type": "Interval",
        "sourceText": "bid"
      },
      {
        "id": "rep_interval_2",
        "type": "Interval",
        "sourceText": "tid"
      },
      {
        "id": "rep_window_1",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P16D",
        "sourceText": "Week 8 to Week 16"
      },
      {
        "id": "rep_window_2",
        "type": "Continuous",
        "endOffset": "P3D",
        "sourceText": "Weeks\n0 to 3"
      },
      {
        "id": "rep_window_3",
        "type": "Continuous",
        "startOffset": "P4D",
        "endOffset": "P7D",
        "sourceText": "Weeks\n4 to 7"
      },
      {
        "id": "rep_window_4",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P11D",
        "sourceText": "Weeks\n8 to 11"
      },
      {
        "id": "rep_window_5",
        "type": "Continuous",
        "startOffset": "P12D",
        "endOffset": "P15D",
        "sourceText": "Weeks\n12 to 15"
      },
      {
        "id": "rep_window_6",
        "type": "Continuous",
        "startOffset": "P16D",
        "endOffset": "P19D",
        "sourceText": "Weeks\n16 to 19"
      },
      {
        "id": "rep_window_7",
        "type": "Continuous",
        "startOffset": "P20D",
        "endOffset": "P104D",
        "sourceText": "Weeks\n20 to 104"
      },
      {
        "id": "rep_window_8",
        "type": "Continuous",
        "startOffset": "P8D",
        "endOffset": "P16D",
        "sourceText": "from Week 8 to Week 16"
      },
      {
        "id": "rep_window_9",
        "type": "Continuous",
        "sourceText": "treatment period"
      },
      {
        "id": "rep_window_10",
        "type": "Continuous",
        "sourceText": "Treatment Period"
      },
      {
        "id": "rep_window_16",
        "type": "Continuous",
        "sourceText": "follow-up period"
      },
      {
        "id": "rep_window_18",
        "type": "Continuous",
        "sourceText": "2 \nhours after"
      },
      {
        "id": "rep_llm_1",
        "type": "Daily",
        "startOffset": "null",
        "endOffset": "null",
        "interval": "P1D",
        "exitCondition": "null",
        "sourceText": "Ability to Perform Physical Activities of Daily Living (APPADL)"
      }
    ],
    "samplingConstraints": [],
    "traversalConstraints": [
      {
        "id": "traversal_1",
        "requiredSequence": [
          "SCREENING",
          "LEAD_IN",
          "TREATMENT",
          "SAFETY_FOLLOW_UP",
          "END_OF_STUDY"
        ],
        "allowEarlyExit": true,
        "exitEpochIds": [
          "EARLY_TERMINATION"
        ],
        "mandatoryVisits": [
          "Screening",
          "Visit 24 (Primary Endpoint)",
          "Randomization",
          "End of Study",
          "Visit 1",
          "Visit 801 (Safety Follow-up)",
          "Visit 3",
          "Visit 2 (Randomization)"
        ],
        "sourceText": "[{'condition': 'Permanent Discontinuation from Study Treatment', 'path': ['EARLY_TERMINATION_VISIT', 'CONTINUED_STUDY_OBSERVATION', 'SAFETY_FOLLOW_UP']}, {'condition': 'Inadvertently Enrolled Patients', 'path': ['DISCONTINUATION']}, {'condition': 'Severe Persistent Hyperglycemia', 'path': ['RESCUE_THERAPY', 'TREATMENT']}]"
      }
    ],
    "executionTypes": [
      {
        "activityId": "Blood Sample",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Vital Signs",
        "executionType": "Single",
        "rationale": "EPISODE signals: 1; SINGLE signals: 2"
      },
      {
        "activityId": "Electrocardiogram",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 1"
      },
      {
        "activityId": "Pe",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Adverse Events",
        "executionType": "Single",
        "rationale": "SINGLE signals: 5"
      },
      {
        "activityId": "Concomitant \nMedications",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Laboratory Tests",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Pharmacokinetic",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Pharmacodynamic",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Drug Administration",
        "executionType": "Episode",
        "rationale": "EPISODE signals: 2"
      },
      {
        "activityId": "Imaging",
        "executionType": "Single",
        "rationale": "SINGLE signals: 2"
      },
      {
        "activityId": "Epro",
        "executionType": "Single",
        "rationale": "No strong signals detected"
      },
      {
        "activityId": "Inclusion and Exclusion Criteria Assessment",
        "executionType": "Single",
        "rationale": "Criteria are assessed at screening to determine eligibility for the study."
      },
      {
        "activityId": "LY3298176 Administration",
        "executionType": "Single",
        "rationale": "The drug is administered once weekly throughout the study duration."
      },
      {
        "activityId": "Insulin Glargine Titration",
        "executionType": "Single",
        "rationale": "Dosing involves adjustments based on glucose readings to reach a specific target."
      },
      {
        "activityId": "Glucose Monitoring",
        "executionType": "Single",
        "rationale": "Continuous or repeated monitoring of glucose levels over the course of the treatment period."
      }
    ],
    "footnoteConditions": [
      {
        "id": "fn_cond_1",
        "conditionType": "timing_before",
        "text": "a. Baseline assessments must be completed before processing in the interactive web-response system (IWRS).",
        "footnoteId": "fn_1",
        "structuredCondition": "sequence.before(baseline_assessments, IWRS_processing)",
        "appliesToActivityIds": [
          "Baseline assessments"
        ],
        "sourceText": "a. Baseline assessments must be completed before processing in the interactive web-response system ("
      },
      {
        "id": "fn_cond_2",
        "conditionType": "timing_after",
        "text": "b. Patients who are unable or unwilling to continue in the study for any reason will perform an ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as the ET visit. If the patient is discontinuing during a scheduled visit, that visit should be performed as an ET visit. Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit.",
        "footnoteId": "fn_2",
        "structuredCondition": "timing.after(ET_visit, P4W)",
        "appliesToActivityIds": [
          "Visit 801",
          "Safety follow-up visit"
        ],
        "sourceText": "b. Patients who are unable or unwilling to continue in the study for any reason will perform an ET v"
      },
      {
        "id": "fn_cond_3",
        "conditionType": "general",
        "text": "c. The visit date is determined in relation to the date of the randomization visit (± the allowed visit window).",
        "footnoteId": "fn_3",
        "sourceText": "c. The visit date is determined in relation to the date of the randomization visit (± the allowed vi"
      },
      {
        "id": "fn_cond_4",
        "conditionType": "timing_before",
        "text": "d. On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients should be reminded to report to the site in a fasting condition, after a period of approximately 8 hours without eating, drinking (except water), or any significant physical activity and before taking study drug(s), metformin (if used), SGLT-2i (if used), SU (if used).",
        "footnoteId": "fn_4",
        "structuredCondition": "timing.after(fasting, PT8H) && timing.before(study_drug, PT0M)",
        "appliesToActivityIds": [
          "Visit 3",
          "Visit 5",
          "Visit 7",
          "Visit 11",
          "Visit 13",
          "Visit 15",
          "Visit 16",
          "Visit 18",
          "Visit 23",
          "Visit 24",
          "Visit 27",
          "Visit 29",
          "ET",
          "Follow-up 801"
        ],
        "timingConstraint": "PT8H",
        "sourceText": "d. On visits 3, 5, 7, 11, 13, 15, 16, 18, 23, 24, 27, 29, ET, and at follow-up (801), patients shoul"
      },
      {
        "id": "fn_cond_5",
        "conditionType": "general",
        "text": "e. Medical history includes assessment of preexisting conditions (including history of gall bladder disease, cardiovascular disease, and medullary thyroid carcinoma) and substance usage (such as, alcohol and tobacco).",
        "footnoteId": "fn_5",
        "sourceText": "e. Medical history includes assessment of preexisting conditions (including history of gall bladder "
      },
      {
        "id": "fn_cond_6",
        "conditionType": "general",
        "text": "f. Weight measurements should be obtained per the detailed guidance in the Manual of Operations.",
        "footnoteId": "fn_6",
        "sourceText": "f. Weight measurements should be obtained per the detailed guidance in the Manual of Operations."
      },
      {
        "id": "fn_cond_7",
        "conditionType": "timing_before",
        "text": "g. Vital sign measurements should be taken before obtaining an ECG tracing and before collection of blood samples for laboratory testing, at visits where required. The participant should sit quietly for 5 minutes before vital sign measurements are taken. For each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. BP must be taken with an automated blood pressure machine.",
        "footnoteId": "fn_7",
        "structuredCondition": "timing.before(vital sign measurements are taken. for each parameter, 2 measurements will be taken using the same arm; the recordings should be taken at least 1 minute apart. bp must be taken with an automated blood pressure machine., PT5M)",
        "appliesToActivityIds": [
          "Vital sign measurements",
          "ECG",
          "Blood samples"
        ],
        "timingConstraint": "PT5M",
        "sourceText": "g. Vital sign measurements should be taken before obtaining an ECG tracing and before collection of "
      },
      {
        "id": "fn_cond_8",
        "conditionType": "procedure_conditional",
        "text": "h. Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy and/or maculopathy. The results from this exam will be recorded on a specific retinopathy eCRF as a baseline measure of retinopathy. A follow-up dilated fundoscopic exam should be performed when clinically indicated by any adverse event suspected of worsening retinopathy, and the findings should be recorded on the retinopathy eCRF.",
        "footnoteId": "fn_8",
        "structuredCondition": "timing.between(Visit_2, Visit_3)",
        "appliesToActivityIds": [
          "Dilated fundoscopic exam"
        ],
        "sourceText": "h. Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optome"
      },
      {
        "id": "fn_cond_9",
        "conditionType": "general",
        "text": "i. Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc.",
        "footnoteId": "fn_9",
        "sourceText": "i. Includes counseling on diet and exercise, management of hypoglycemia and hyperglycemia, etc."
      },
      {
        "id": "fn_cond_10",
        "conditionType": "general",
        "text": "j. All training should be repeated as needed to ensure patient compliance.",
        "footnoteId": "fn_10",
        "sourceText": "j. All training should be repeated as needed to ensure patient compliance."
      },
      {
        "id": "fn_cond_11",
        "conditionType": "timing_before",
        "text": "k. Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. A 7-point SMBG consists of measurements before and 2 hours after each of 3 main meals within the same day and at bedtime. These SMBG profiles will be collected by the patient within 2 weeks prior to the assigned visits. If 7-point SMBG is not performed, then data from the most recent nonconsecutive 4-point SMBG profiles can be used. If more than 2 SMBG profiles are available, the 2 most recent nonconsecutive profiles should be used.",
        "footnoteId": "fn_11",
        "structuredCondition": "timing.after(each of 3 main meals within the same day and at bedtime. these smbg profiles will be collected by the patient within 2 weeks prior to the assigned visits. if 7-point smbg is not performed, then data from the most recent nonconsecutive 4-point smbg profiles can be used. if more than 2 smbg profiles are available, the 2 most recent nonconsecutive profiles should be used., PT2M)",
        "appliesToActivityIds": [
          "7-point SMBG"
        ],
        "timingConstraint": "PT2H",
        "sourceText": "k. Patient is required to collect two 7-point SMBGs on nonconsecutive days prior to the next visit. "
      },
      {
        "id": "fn_cond_12",
        "conditionType": "timing_after",
        "text": "l. Patients should administer their first dose of LY3298176 at the end of this visit, after other study procedures and randomization.",
        "footnoteId": "fn_12",
        "structuredCondition": "sequence.after(first_dose, study_procedures) && sequence.after(first_dose, randomization)",
        "appliesToActivityIds": [
          "First dose of LY3298176"
        ],
        "sourceText": "l. Patients should administer their first dose of LY3298176 at the end of this visit, after other st"
      },
      {
        "id": "fn_cond_13",
        "conditionType": "general",
        "text": "m. LY3298176 patients only.",
        "footnoteId": "fn_13",
        "structuredCondition": "patient.cohort == 'LY3298176'",
        "appliesToActivityIds": [
          "All activities marked 'm'"
        ],
        "sourceText": "m. LY3298176 patients only."
      },
      {
        "id": "fn_cond_14",
        "conditionType": "timing_after",
        "text": "n. During the first 8 weeks, the dose adjustment will be determined by the investigator in discussion with the patient by following a TTT algorithm. After Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm.",
        "footnoteId": "fn_14",
        "sourceText": "n. During the first 8 weeks, the dose adjustment will be determined by the investigator in discussio"
      },
      {
        "id": "fn_cond_15",
        "conditionType": "procedure_timepoints",
        "text": "o. Insulin glargine patients only. A review of the patient's compliance to the TTT algorithm will still be conducted during the telephone Visits 6, 8, 9, and 12, but the patient's compliance for these visits will be collected in the eCRF at Visits 7, 10 and 13 for the period since the previous visit.",
        "footnoteId": "fn_15",
        "structuredCondition": "patient.cohort == 'Insulin glargine'",
        "appliesToActivityIds": [
          "Visit 6",
          "Visit 8",
          "Visit 9",
          "Visit 12"
        ],
        "sourceText": "o. Insulin glargine patients only. A review of the patient's compliance to the TTT algorithm will st"
      },
      {
        "id": "fn_cond_16",
        "conditionType": "eligibility_wocbp",
        "text": "p. A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only.",
        "footnoteId": "fn_16",
        "structuredCondition": "subject.sex == 'Female' AND subject.isOfChildbearingPotential == true",
        "appliesToActivityIds": [
          "Serum pregnancy test"
        ],
        "sourceText": "p. A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only."
      },
      {
        "id": "fn_cond_17",
        "conditionType": "timing_before",
        "text": "q. A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy tests may be performed at the investigator's discretion during the study. If required per local regulations and/or institutional guidelines, pregnancy testing can also occur at other times during the study treatment period.",
        "footnoteId": "fn_17",
        "structuredCondition": "sequence.before(urine_pregnancy_test, randomization) && sequence.before(urine_pregnancy_test, first_injection)",
        "appliesToActivityIds": [
          "Urine pregnancy test"
        ],
        "sourceText": "q. A urine pregnancy test must be performed at Visit 3 with the result available prior to randomizat"
      },
      {
        "id": "fn_cond_18",
        "conditionType": "procedure_timepoints",
        "text": "r. Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years of age with an intact uterus, without a history of oophorectomy or bilateral tubal ligation, not on hormone therapy, and who have had spontaneous amenorrhea for more than 6 months and less than 12 months.",
        "footnoteId": "fn_18",
        "sourceText": "r. Follicle-stimulating hormone test performed at Visit 1 for postmenopausal women at least 50 years"
      },
      {
        "id": "fn_cond_19",
        "conditionType": "general",
        "text": "s. Screening visit assessment will serve as baseline.",
        "footnoteId": "fn_19",
        "sourceText": "s. Screening visit assessment will serve as baseline."
      },
      {
        "id": "fn_cond_20",
        "conditionType": "procedure_timepoints",
        "text": "t. The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m², the eGFR value must be confirmed to be <60 mL/min/1.73m² at Visit 2.",
        "footnoteId": "fn_20",
        "sourceText": "t. The CKD-EPI equation will be used by the central lab to estimate and report eGFR. For patients wh"
      },
      {
        "id": "fn_cond_21",
        "conditionType": "general",
        "text": "u. This sample is required only for patients who meet inclusion criterion [4] based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m².",
        "footnoteId": "fn_21",
        "sourceText": "u. This sample is required only for patients who meet inclusion criterion [4] based solely on histor"
      },
      {
        "id": "fn_cond_22",
        "conditionType": "general",
        "text": "v. In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional blood samples will be collected including ADA, PK, and, exploratory biomarker sample.",
        "footnoteId": "fn_22",
        "sourceText": "v. In the event of systemic drug hypersensitivity reactions (immediate or nonimmediate), additional "
      },
      {
        "id": "fn_cond_23",
        "conditionType": "timing_before",
        "text": "w. PK sample for immunogenicity must be collected prior to drug administration.",
        "footnoteId": "fn_23",
        "structuredCondition": "sequence.before(PK_sample, drug_administration)",
        "appliesToActivityIds": [
          "PK sample"
        ],
        "sourceText": "w. PK sample for immunogenicity must be collected prior to drug administration."
      },
      {
        "id": "fn_cond_24",
        "conditionType": "timing_before",
        "text": "x. PK samples will not be collected from patients who were randomized to insulin glargine since it is an open-label study. PK samples will be collected at these visits at time windows of 1 to 24 hours, 24 to 96 hours, OR 120 to 168 hours post dose, as assigned by IWRS. Dependent on the time-windows to which a patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but only those patients assigned to PK will get a PK blood draw. Visits 17 and 21 are for patients assigned to a PK blood draw only.",
        "footnoteId": "fn_24",
        "timingConstraint": "PT24H",
        "sourceText": "x. PK samples will not be collected from patients who were randomized to insulin glargine since it i"
      },
      {
        "id": "fn_cond_25",
        "conditionType": "timing_before",
        "text": "y. PROs should be completed before any other study procedures if the patient is not adversely affected by the fasting condition or completed after the patient has sufficiently recovered from the preceding visit procedures.",
        "footnoteId": "fn_25",
        "structuredCondition": "sequence.before(PRO, other_procedures)",
        "appliesToActivityIds": [
          "PROs"
        ],
        "sourceText": "y. PROs should be completed before any other study procedures if the patient is not adversely affect"
      },
      {
        "id": "fn_cond_26",
        "conditionType": "timing_after",
        "text": "z. When the sponsor determines that the study has met the completion criteria, all patients remaining in the study will return to the site for a FTV within approximately 30 days. The safety follow-up visit will be approximately 30 days after the FTV.",
        "footnoteId": "fn_26",
        "structuredCondition": "timing.after(study_completion, P30D)",
        "appliesToActivityIds": [
          "FTV",
          "Safety follow-up visit"
        ],
        "sourceText": "z. When the sponsor determines that the study has met the completion criteria, all patients remainin"
      },
      {
        "id": "fn_cond_27",
        "conditionType": "procedure_timepoints",
        "text": "4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must be confirmed to be <60 mL/min/1.73m2 at Visit 2. u This sample is required only for patients who meet inclusion criterion",
        "footnoteId": "fn_27",
        "sourceText": "4. based solely on history of chronic kidney disease and eGFR <60 mL/min/1.73m2, the eGFR value must"
      },
      {
        "id": "fn_cond_28",
        "conditionType": "general",
        "text": "1. Have been diagnosed with T2DM based on the World Health Organization classification or other locally applicable diagnostic standards Patient Characteristics",
        "footnoteId": "fn_28",
        "sourceText": "1. Have been diagnosed with T2DM based on the World Health Organization classification or other loca"
      },
      {
        "id": "fn_cond_29",
        "conditionType": "procedure_timepoints",
        "text": "2. Have HbA1c between ≥7.5% (58 mmol/mol) and ≤10.5% (91 mmol/mol) at screening as determined by the central laboratory at Visit 1",
        "footnoteId": "fn_29",
        "sourceText": "2. Have HbA1c between ≥7.5% (58 mmol/mol) and ≤10.5% (91 mmol/mol) at screening as determined by the"
      },
      {
        "id": "fn_cond_30",
        "conditionType": "timing_before",
        "text": "3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic drugs, which may only include metformin, SGLT-2i, and/or sulfonylurea for at least 3 months before Visit 1",
        "footnoteId": "fn_30",
        "sourceText": "3. On stable treatment with unchanged dose of at least 1 and no more than 3 oral antihyperglycemic d"
      },
      {
        "id": "fn_cond_31",
        "conditionType": "general",
        "text": "6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as protocol waivers or exemptions, are not permitted.",
        "footnoteId": "fn_31",
        "sourceText": "6. Study Population Prospective approval of protocol deviations to recruitment and enrollment criter"
      },
      {
        "id": "fn_cond_32",
        "conditionType": "general",
        "text": "5. Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress test",
        "footnoteId": "fn_32",
        "sourceText": "5. Asymptomatic cardiac ischemia documented by cardiac imaging on exercise or pharmacological stress"
      }
    ],
    "endpointAlgorithms": [
      {
        "id": "ep_1",
        "name": "Primary: Mean change in HbA1c",
        "endpointType": "Primary",
        "inputs": [
          "HbA1c at baseline",
          "HbA1c at 52 weeks"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 52",
          "duration": "P52W"
        },
        "algorithm": "Week 52 HbA1c - Baseline HbA1c",
        "successCriteria": "Noninferiority of LY3298176 10 mg and/or 15 mg to insulin glargine (2-sided 0.05 significance level)",
        "sourceText": "The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks."
      },
      {
        "id": "ep_2",
        "name": "Key Secondary: Mean change in HbA1c (5 mg)",
        "endpointType": "Secondary",
        "inputs": [
          "HbA1c at baseline",
          "HbA1c at 52 weeks"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 52",
          "duration": "P52W"
        },
        "algorithm": "Week 52 HbA1c - Baseline HbA1c",
        "successCriteria": "Noninferiority of LY3298176 5 mg to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg is noninferior to insulin glargine for change from baseline in HbA1c at 52 weeks"
      },
      {
        "id": "ep_3",
        "name": "Key Secondary: Mean change in body weight",
        "endpointType": "Secondary",
        "inputs": [
          "Body weight at baseline",
          "Body weight at 52 weeks"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 52",
          "duration": "P52W"
        },
        "algorithm": "Week 52 Body Weight - Baseline Body Weight",
        "successCriteria": "Superiority of LY3298176 (5 mg, 10 mg, and/or 15 mg) to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in weight at 52 weeks"
      },
      {
        "id": "ep_4",
        "name": "Key Secondary: Superiority in HbA1c",
        "endpointType": "Secondary",
        "inputs": [
          "HbA1c at baseline",
          "HbA1c at 52 weeks"
        ],
        "timeWindow": {
          "reference": "Baseline to Week 52",
          "duration": "P52W"
        },
        "algorithm": "Week 52 HbA1c - Baseline HbA1c",
        "successCriteria": "Superiority of LY3298176 (5 mg, 10 mg, and/or 15 mg) to insulin glargine",
        "sourceText": "To demonstrate that QW LY3298176 5 mg, 10 mg, and/or 15 mg is superior to insulin glargine for change from baseline in HbA1c at 52 weeks"
      }
    ],
    "derivedVariables": [
      {
        "id": "dv_1",
        "name": "Change from Baseline in HbA1c",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "HbA1c_at_52_weeks - HbA1c_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "Modified intention-to-treat (mITT) population analysis",
        "unit": "%"
      },
      {
        "id": "dv_2",
        "name": "Change from Baseline in Body Weight",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Weight"
        ],
        "derivationRule": "Weight_at_52_weeks - Weight_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "kg"
      },
      {
        "id": "dv_3",
        "name": "HbA1c Target <7.0%",
        "variableType": "Categorical",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "If HbA1c < 7.0% then 1 else 0",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "Boolean"
      },
      {
        "id": "dv_4",
        "name": "Change from Baseline in Fasting Serum Glucose",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Fasting Serum Glucose"
        ],
        "derivationRule": "FSG_at_52_weeks - FSG_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "mg/dL or mmol/L"
      },
      {
        "id": "dv_5",
        "name": "HbA1c Target ≤6.5%",
        "variableType": "Categorical",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "If HbA1c <= 6.5% then 1 else 0",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "Boolean"
      },
      {
        "id": "dv_6",
        "name": "HbA1c Target <5.7%",
        "variableType": "Categorical",
        "sourceVariables": [
          "HbA1c"
        ],
        "derivationRule": "If HbA1c < 5.7% then 1 else 0",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "Boolean"
      },
      {
        "id": "dv_7",
        "name": "Weight Loss Categories (≥5%, >10%, >15%)",
        "variableType": "PercentChange",
        "sourceVariables": [
          "Weight"
        ],
        "derivationRule": "((Weight_at_52_weeks - Weight_at_baseline) / Weight_at_baseline) * 100",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "%"
      },
      {
        "id": "dv_8",
        "name": "Change from Baseline in Blood Pressure and Heart Rate",
        "variableType": "ChangeFromBaseline",
        "sourceVariables": [
          "Systolic Blood Pressure",
          "Diastolic Blood Pressure",
          "Heart Rate"
        ],
        "derivationRule": "Value_at_52_weeks - Value_at_baseline",
        "baselineDefinition": "Value at randomization/baseline",
        "baselineVisit": "Baseline",
        "analysisWindow": "52 weeks",
        "imputationRule": "mITT",
        "unit": "mmHg / bpm"
      },
      {
        "id": "dv_9",
        "name": "Time to initiation of rescue therapy",
        "variableType": "TimeToEvent",
        "sourceVariables": [
          "Rescue Therapy Date",
          "Randomization Date"
        ],
        "derivationRule": "Rescue_Therapy_Date - Randomization_Date",
        "baselineDefinition": "Date of Randomization",
        "baselineVisit": "Day 1",
        "analysisWindow": "Up to 52 weeks and follow-up",
        "imputationRule": "Censoring at last contact if no rescue",
        "unit": "Days"
      },
      {
        "id": "dv_10",
        "name": "Composite CV Endpoint",
        "variableType": "Composite",
        "sourceVariables": [
          "CV Death",
          "Myocardial Infarction",
          "Stroke",
          "Hospitalization for Unstable Angina"
        ],
        "derivationRule": "Occurrence of any of the 4 component events",
        "baselineDefinition": "N/A",
        "baselineVisit": "N/A",
        "analysisWindow": "Study duration",
        "imputationRule": "Adjudicated events",
        "unit": "Boolean"
      }
    ],
    "stateMachine": {
      "id": "sm_1",
      "initialState": "Screening",
      "terminalStates": [
        "Early Termination",
        "Completed"
      ],
      "states": [
        "Screening",
        "Lead In",
        "Treatment",
        "Safety Follow Up",
        "End Of Study",
        "Early Termination"
      ],
      "transitions": [
        {
          "fromState": "Screening",
          "toState": "Lead In",
          "trigger": "Progress to Lead In"
        },
        {
          "fromState": "Lead In",
          "toState": "Treatment",
          "trigger": "Progress to Treatment"
        },
        {
          "fromState": "Treatment",
          "toState": "Safety Follow Up",
          "trigger": "Progress to Safety Follow Up"
        },
        {
          "fromState": "Safety Follow Up",
          "toState": "End Of Study",
          "trigger": "Progress to End Of Study"
        },
        {
          "fromState": "Treatment",
          "toState": "Early Termination",
          "trigger": "Subject exits to Early Termination"
        }
      ],
      "epochIds": {
        "Screening": "SCREENING",
        "Lead_In": "LEAD_IN",
        "Treatment": "TREATMENT",
        "Safety_Follow_Up": "SAFETY_FOLLOW_UP",
        "End_Of_Study": "END_OF_STUDY",
        "Early_Termination": "EARLY_TERMINATION"
      }
    },
    "dosingRegimens": [
      {
        "id": "dosing_1",
        "treatmentName": "QW LY3298176",
        "frequency": "QW",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "durationDescription": "52 weeks",
        "sourceText": "ascular (CV) risk. The primary endpoint will be the mean change in hemoglobin A1c (HbA1c) levels from baseline to 52 weeks. Objective(s)/Endpoints: Objectives Endpoints Primary  To demonstrate that Q"
      },
      {
        "id": "dosing_2",
        "treatmentName": "with LY3298176",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "sourceText": "uate the relationship between LY3298176 exposure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control wit"
      },
      {
        "id": "dosing_3",
        "treatmentName": "compare LY3298176",
        "frequency": "QD",
        "route": "Oral",
        "startDay": 1,
        "doseLevels": [
          {
            "amount": 5.0,
            "unit": "mg"
          },
          {
            "amount": 10.0,
            "unit": "mg"
          },
          {
            "amount": 15.0,
            "unit": "mg"
          }
        ],
        "sourceText": "posure and safety, tolerability, and efficacy measures  Population PK and PD parameters Tertiary/Exploratory  To characterize long-term glycemic control with LY3298176 5 mg, 10 mg, and 15 mg  To co"
      },
      {
        "id": "dosing_llm_1",
        "treatmentName": "LY3298176",
        "frequency": "QW",
        "route": "SC",
        "startDay": 1,
        "durationDescription": "Not specified in provided text",
        "titrationSchedule": "Mentioned in Section 7.4.1 'Study Drugs' and 7.2.1.1, though specific increments are not in this excerpt.",
        "doseModifications": [
          "Dosage modification details located in Section 7.4"
        ]
      },
      {
        "id": "dosing_llm_2",
        "treatmentName": "Insulin Glargine",
        "frequency": "QD",
        "route": "SC",
        "startDay": 1,
        "durationDescription": "Not specified in provided text",
        "titrationSchedule": "Mentioned in Section 7.2.1.2 and 7.4.1.",
        "doseModifications": [
          "Reduction and/or Discontinuation of Concomitant Antihyperglycemic Medications (Section 7.4.2)"
        ]
      }
    ],
    "visitWindows": [
      {
        "id": "visit_6",
        "visitName": "Screening",
        "targetDay": -14,
        "windowBefore": 7,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 1,
        "sourceText": "Screening Lead in Treatment Period"
      },
      {
        "id": "visit_1",
        "visitName": "Early Termination",
        "targetDay": null,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 2,
        "sourceText": "HbA1c target values of <7.0% (53 mmol/mol) at 52 weeks "
      },
      {
        "id": "visit_2",
        "visitName": "baseline",
        "targetDay": 0,
        "windowBefore": 1,
        "windowAfter": 1,
        "isRequired": true,
        "visitNumber": 3,
        "sourceText": "(central laboratory) from baseline  The proportion of patients achieving an HbA1c"
      },
      {
        "id": "visit_7",
        "visitName": "Visit 801",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "epoch": "Study Period IV: Safety F/U",
        "sourceText": "Visit 801 (safety follow-up visit) should be performed 4 weeks after the ET visit as the final study visit. c The visit date is determined in relation to the date of the randomization visit (± the all"
      },
      {
        "id": "visit_8",
        "visitName": "Visit 2",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "epoch": "Study Period I: Lead in",
        "sourceText": "Dilated fundoscopic exam will be performed by an eye care professional (ophthalmologist or optometrist) for all patients between Visit 2 and Visit 3 to exclude patients with proliferative retinopathy "
      },
      {
        "id": "visit_11",
        "visitName": "Visit 1",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "epoch": "Study Period I: Screening",
        "sourceText": "A serum pregnancy test will be performed at Visit 1 for women of childbearing potential only. q A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and"
      },
      {
        "id": "visit_12",
        "visitName": "Visit 3",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "A urine pregnancy test must be performed at Visit 3 with the result available prior to randomization and first injection of study drug(s) for women of childbearing potential only. Additional pregnancy"
      },
      {
        "id": "visit_14",
        "visitName": "Visit 25",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "epoch": "Study Period III: Treatment Period",
        "sourceText": "Long-term safety period (Visit 25 to Visit 29): Some patients will continue to receive LY3298176 or insulin glargine for up to, but not longer than, 24 months, as determined by the sponsor."
      },
      {
        "id": "visit_15",
        "visitName": "Visit 29",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "epoch": "Study Period III: Treatment Period",
        "sourceText": "attend Visit 29 (24 months) or the FTV are considered to have completed the treatment period. Study Period IV (safety follow-up period) Safety follow-up (Visit 801) visits:"
      },
      {
        "id": "visit_16",
        "visitName": "End of Study",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 10,
        "sourceText": "End of Study Definition End of the study is the date of the last visit or last scheduled procedure shown in the Schedule of Activities (Section 2) for the last patient."
      },
      {
        "id": "visit_17",
        "visitName": "Visit 13",
        "targetDay": null,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": false,
        "visitNumber": 11,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "scheduled visits, the IWRS will have unscheduled visits (for example, Visit 13a) dedicated to provide dispensing information for patients whose dose has been de-escalated. Those patients who have thei"
      },
      {
        "id": "visit_4",
        "visitName": "randomization",
        "targetDay": 1,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 12,
        "sourceText": "or insulin glargine. The randomization will be stratified by country, baseline HbA1c concentration (≤8.5%, ˃8.5% [≤69, ˃69 mmol/mol]), and sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use (Yes"
      },
      {
        "id": "visit_llm_4",
        "visitName": "Visit 4",
        "targetDay": 8,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 4,
        "targetWeek": 1,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_5",
        "visitName": "Visit 5",
        "targetDay": 15,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 5,
        "targetWeek": 2,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_6",
        "visitName": "Visit 6",
        "targetDay": 22,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 6,
        "targetWeek": 3,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_7",
        "visitName": "Visit 7",
        "targetDay": 29,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 7,
        "targetWeek": 4,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_8",
        "visitName": "Visit 8",
        "targetDay": 36,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 8,
        "targetWeek": 5,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_9",
        "visitName": "Visit 9",
        "targetDay": 43,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 9,
        "targetWeek": 6,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_9",
        "visitName": "Week 8",
        "targetDay": 50,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 8,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "Week 8, the dose adjustment will be determined by the patient in a weekly manner and will be reviewed by the investigator at each office visit. Patient will have weekly visits (clinic or phone) in the"
      },
      {
        "id": "visit_llm_11",
        "visitName": "Visit 11",
        "targetDay": 57,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 11,
        "targetWeek": 8,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_12",
        "visitName": "Visit 12",
        "targetDay": 71,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 12,
        "targetWeek": 10,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_10",
        "visitName": "Week 16",
        "targetDay": 106,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 16,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "have weekly visits (clinic or phone) in the first 8 weeks and then visits every 2-3 weeks (clinic or phone) until Week 16 in order to improve compliance with the TTT algorithm. o"
      },
      {
        "id": "visit_llm_15",
        "visitName": "Visit 15",
        "targetDay": 113,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 15,
        "targetWeek": 16,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_16",
        "visitName": "Visit 16",
        "targetDay": 141,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 16,
        "targetWeek": 20,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_18",
        "visitName": "Week 24",
        "targetDay": 162,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 25,
        "targetWeek": 24,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "(Week 24), dose decreases will not be permitted. 7.8. Treatment after the End of the Study"
      },
      {
        "id": "visit_llm_18",
        "visitName": "Visit 18",
        "targetDay": 169,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 18,
        "targetWeek": 24,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_19",
        "visitName": "Visit 19",
        "targetDay": 197,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 19,
        "targetWeek": 28,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_20",
        "visitName": "Visit 20",
        "targetDay": 225,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 20,
        "targetWeek": 32,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_13",
        "visitName": "Week 35",
        "targetDay": 239,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 29,
        "targetWeek": 35,
        "sourceText": "patient gets assigned, they may be required to come to site for PK-specific visits. Draw PK at ET visit only if patient discontinues study prior to Week 35. Visits 10 and 14 are for all patients, but "
      },
      {
        "id": "visit_llm_21",
        "visitName": "Visit 21",
        "targetDay": 246,
        "windowBefore": 0,
        "windowAfter": 0,
        "isRequired": true,
        "visitNumber": 21,
        "targetWeek": 35,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_22",
        "visitName": "Visit 22",
        "targetDay": 253,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 22,
        "targetWeek": 36,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_llm_23",
        "visitName": "Visit 23",
        "targetDay": 295,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 23,
        "targetWeek": 42,
        "epoch": "Study Period II: Treatment Period"
      },
      {
        "id": "visit_5",
        "visitName": "Week 52",
        "targetDay": 358,
        "windowBefore": 3,
        "windowAfter": 3,
        "isRequired": true,
        "visitNumber": 33,
        "targetWeek": 52,
        "sourceText": "same treatment arm who had their efficacy measure at the Week 52 visit assessed after early discontinuation of study drug and/or initiation of rescue medication (retrieved dropouts). Analysis will be "
      },
      {
        "id": "visit_3",
        "visitName": "Follow-up",
        "targetDay": 365,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 34,
        "epoch": "Study Period II: Treatment Period",
        "sourceText": "safety follow-up period, with respect to the following outcomes "
      },
      {
        "id": "visit_llm_26",
        "visitName": "Visit 26",
        "targetDay": 505,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 26,
        "targetWeek": 72,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_27",
        "visitName": "Visit 27",
        "targetDay": 547,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 27,
        "targetWeek": 78,
        "epoch": "Study Period III: Treatment Period"
      },
      {
        "id": "visit_llm_28",
        "visitName": "Visit 28",
        "targetDay": 617,
        "windowBefore": 7,
        "windowAfter": 7,
        "isRequired": true,
        "visitNumber": 28,
        "targetWeek": 88,
        "epoch": "Study Period III: Treatment Period"
      }
    ],
    "randomizationScheme": {
      "id": "randomization_1",
      "ratio": "1:1:1:3",
      "method": "Stratified randomization",
      "centralRandomization": true,
      "stratificationFactors": [
        {
          "id": "strat_1",
          "name": "Country",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "country, baseline hba1c concentration (≤8"
        },
        {
          "id": "strat_2",
          "name": "Baseline",
          "categories": [
            "Category 1",
            "Category 2"
          ],
          "isBlocking": false,
          "sourceText": "country, baseline hba1c concentration (≤8"
        },
        {
          "id": "strat_llm_2",
          "name": "Baseline HbA1c concentration",
          "categories": [
            "≤8.5% (≤69 mmol/mol)",
            ">8.5% (>69 mmol/mol)"
          ],
          "isBlocking": false
        },
        {
          "id": "strat_llm_3",
          "name": "Sodium-glucose co-transporter-2 inhibitors (SGLT-2i) use",
          "categories": [
            "Yes",
            "No"
          ],
          "isBlocking": false
        }
      ],
      "sourceText": "I8F-MC-GPGM(b) Clinical Protocol\nPage 11\nLY3298176\nSummary of Study Design:  \nStudy GPGM is a Phase 3, open-label comparator, multicenter, parallel-arm, randomized study to compare the \nsafety and eff"
    },
    "analysisWindows": [
      {
        "id": "window_treatment_1",
        "windowType": "treatment",
        "name": "Treatment Period",
        "startDay": 3,
        "endDay": 2,
        "description": "Active treatment from Day 3 to Day 2",
        "sourceText": "Treatment\n-3\n-2"
      }
    ]
  }
}